Cargando…

Rearranged During Transfection Fusions in Non-Small Cell Lung Cancer

Identifying and targeting specific oncogenic drivers has become standard of care in the routine management of patients with lung cancer. Research is ongoing to expand the number of drug targets that can offer clinically meaningful outcomes. Rearranged during transfection (RET) fusions are the latest...

Descripción completa

Detalles Bibliográficos
Autores principales:	O’Leary, Connor, Xu, Wen, Pavlakis, Nick, Richard, Derek, O’Byrne, Ken
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562639/ https://www.ncbi.nlm.nih.gov/pubmed/31058838 http://dx.doi.org/10.3390/cancers11050620

Ejemplares similares

High-Plex and High-Throughput Digital Spatial Profiling of Non-Small-Cell Lung Cancer (NSCLC)
por: Monkman, James, et al.
Publicado: (2020)

Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)
por: O’Leary, Connor, et al.
Publicado: (2020)

Computed tomography texture analysis of response to second-line nivolumab in metastatic non-small cell lung cancer
por: Ladwa, Rahul, et al.
Publicado: (2020)

Unilateral autoimmune inner ear disease in a patient with lung cancer treated with nivolumab
por: Rajapakse, Aleksandra, et al.
Publicado: (2020)

Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?
por: Ahern, Elizabeth, et al.
Publicado: (2021)

Anti-Angiogenic Therapy in ALK Rearranged Non-Small Cell Lung Cancer (NSCLC)
por: Tan, Aaron C., et al.
Publicado: (2022)

Comparison of Rearranged During Transfection (RET) Gene Rearrangements in Primary Versus Metastatic Non-Small Cell Lung Cancer (NSCLC)
por: Zhang, Quxia, et al.
Publicado: (2018)

Expanded Access Program Pralsetinib in Advanced Non–Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement
por: Jeon, Youngkyung, et al.
Publicado: (2023)

Epigenetic Mechanisms in DNA Double Strand Break Repair: A Clinical Review
por: Fernandez, Alejandra, et al.
Publicado: (2021)

Generation and Characterisation of Cisplatin-Resistant Non-Small Cell Lung Cancer Cell Lines Displaying a Stem-Like Signature
por: Barr, Martin P., et al.
Publicado: (2013)

Correction: Generation and Characterisation of Cisplatin-Resistant Non-Small Cell Lung Cancer Cell Lines Displaying a Stem-Like Signature
por: Barr, Martin P., et al.
Publicado: (2020)

The Therapeutic Potential of DNA Damage Repair Pathways and Genomic Stability in Lung Cancer
por: Burgess, Joshua T., et al.
Publicado: (2020)

Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancer
por: Kapeleris, Joanna, et al.
Publicado: (2022)

Ex vivo culture of circulating tumour cells derived from non-small cell lung cancer
por: Kapeleris, Joanna, et al.
Publicado: (2020)

Identification of Proteins Deregulated by Platinum-Based Chemotherapy as Novel Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer
por: Ryan, Sarah-Louise, et al.
Publicado: (2021)

Pembrolizumab-induced toxic epidermal necrolysis: case report
por: Chow, Kar Ven Cavan, et al.
Publicado: (2022)

First-line versus second-line use of pralsetinib in treatment of rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer: a cost-effectiveness analysis
por: Liu, Wenjie, et al.
Publicado: (2023)

Modelling reoxygenation effects in non-small cell lung cancer cell lines and showing epithelial-mesenchymal transition
por: Kapeleris, Joanna, et al.
Publicado: (2022)

Epidermal growth factor receptor mutated oligometastatic adeno-squamous lung cancer transformation to small cell lung cancer
por: O’Leary, Connor G, et al.
Publicado: (2018)

Epigenetics Underpinning the Regulation of the CXC (ELR(+)) Chemokines in Non-Small Cell Lung Cancer
por: Baird, Anne-Marie, et al.
Publicado: (2011)

Isolation of circulating tumor cells in non-small-cell-lung-cancer patients using a multi-flow microfluidic channel
por: Zhou, Jian, et al.
Publicado: (2019)

IL-23R is Epigenetically Regulated and Modulated by Chemotherapy in Non-Small Cell Lung Cancer
por: Baird, Anne-Marie, et al.
Publicado: (2013)

Is There Any Mosaicism in REarranged During Transfection Variant in Hirschsprung Disease’s Patients?
por: Iskandar, Kristy, et al.
Publicado: (2022)

MicroRNA expression profiling and biomarker validation in treatment-naïve and drug resistant non-small cell lung cancer
por: MacDonagh, Lauren, et al.
Publicado: (2021)

The quantum leap in therapeutics for advanced ALK+ non-small cell lung cancer and pursuit to cure with precision medicine
por: Itchins, Malinda, et al.
Publicado: (2022)

Epigenetic Regulation of Glucose Transporters in Non-Small Cell Lung Cancer
por: O'Byrne, Kenneth J., et al.
Publicado: (2011)

Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer
por: Swinson, D E B, et al.
Publicado: (2004)

The prognostic significance of circulating tumor cells in head and neck and non‐small‐cell lung cancer
por: Kulasinghe, Arutha, et al.
Publicado: (2018)

SASH1 is a prognostic indicator and potential therapeutic target in non-small cell lung cancer
por: Burgess, Joshua T., et al.
Publicado: (2020)

The Use of Three-Dimensional DNA Fluorescent In Situ Hybridization (3D DNA FISH) for the Detection of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer (NSCLC) Circulating Tumor Cells
por: Kulasinghe, Arutha, et al.
Publicado: (2020)

Monomerization of ALK Fusion Proteins as a Therapeutic Strategy in ALK-Rearranged Non-small Cell Lung Cancers
por: Hirai, Noriko, et al.
Publicado: (2020)

Defining COMMD4 as an anti-cancer therapeutic target and prognostic factor in non-small cell lung cancer
por: Suraweera, Amila, et al.
Publicado: (2020)

Correction: Defining COMMD4 as an anti-cancer therapeutic target and prognostic factor in non-small cell lung cancer
por: Suraweera, Amila, et al.
Publicado: (2021)

Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer
por: Barr, Martin P, et al.
Publicado: (2015)

Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer
por: Cathcart, Mary-Clare, et al.
Publicado: (2011)

ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC)
por: Du, Xue, et al.
Publicado: (2018)

Correction to: Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer
por: Barr, Martin P., et al.
Publicado: (2020)

Anti-cancer effects of baicalein in non-small cell lung cancer in-vitro and in-vivo
por: Cathcart, Mary-Clare, et al.
Publicado: (2016)

Small-cell transformation of ALK-rearranged non-small-cell adenocarcinoma of the lung
por: Balla, Agnes, et al.
Publicado: (2018)

Molecular Modelling Studies on Pyrazole Derivatives for the Design of Potent Rearranged during Transfection Kinase Inhibitors
por: Bhujbal, Swapnil P., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_809h0dcdt7b2ge2s801p77u87n